Market Newsdesk

VANCOUVER, BC, Dec. 1, 2020 /PRNewswire/ – Callinex Mines Inc. (the “Company” or “Callinex”) (TSXV: CNX) (OTC: CLLXF) announces that its officers, directors and key personnel have exercised 176,666 stock options for total proceeds of $256,333.  Of $256,333 proceeds received, a total of $198,000 related to options with an exercise price of $3.30 per share.  By exercising stock options with an above market strike price, management and directors are demonstrating their firm belief in the intrinsic value across the Company’s exploration portfolio.

About Callinex Mines Inc.

Callinex Mines Inc. (TSXV: CNX) (OTC: CLLXF) is advancing its portfolio of base and precious metals rich deposits located in established Canadian mining jurisdictions. The portfolio is highlighted by the rapidly expanding Rainbow Discovery at its Pine Bay Project located near existing infrastructure in the Flin Flon Mining District. Additionally, Callinex has emerging near-surface silver discoveries at its Nash Creek Project located in the Bathurst Mining District of New Brunswick. A 2018 PEA on the Company’s Bathurst projects outlined a mine plan that generates a strong economic return with a pre-tax IRR of 34.1% (25.2% post-tax) and NPV8% of $230 million ($128 million post-tax).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward-looking information. These statements include, but are not limited to, statements with respect to future expenditures. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the ability to complete the proposed drill program and the timing and amount of expenditures. Except as required under applicable securities laws, Callinex does not assume the obligation to update any forward-looking statement.

View original content:http://www.prnewswire.com/news-releases/callinex-announces-stock-option-exercise-301182557.html

SOURCE Callinex Mines Inc.

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Louis Monti, M.D., Ph.D., a pioneer in the research and development of neuroactive steroids known as “pherines,” including VistaGen’s intranasal drug candidates PH94B for anxiety disorders and PH10 for depression disorders, has joined the Company as Vice President, Translational Medicine.

“We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day,” stated Shawn K. Singh, Chief Executive Officer of VistaGen. “As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti’s unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team.”

Dr. Monti commented, “Driving research of neuroactive pherines to develop innovative medicines with the potential to lift the burdens of anxiety and depression has been a passion throughout my career. I am truly pleased to join a team that shares that sense of commitment and purpose. I am excited that my new role at VistaGen will allow me both to continue to assist with the late-stage clinical development of PH94B and PH10 and apply my R&D experience working with neuroactive steroids to explore potential pipeline expansion opportunities.”

Dr. Monti has served as President and CEO of Pherin Pharmaceuticals since July 2018. He previously served as its Executive Vice President between 2002 and 2018 and as its Vice President of Research from its founding in 1991 to 2002. Prior to joining Pherin, Dr. Monti held various academic positions at the University of Utah and the University of the Republic, Uruguay. He earned an M.D. from the University of the Republic, Uruguay School of Medicine, and a Ph.D. in Physiology and Pharmacology from the University of Utah. Dr. Monti holds memberships in the New York Academy of Sciences, the American Society of Clinical Psychopharmacology, and the International Brain Organization.

About PH94B
PH94B is an innovative odorless investigational synthetic neuroactive steroid nasal spray with therapeutic potential in multiple mental health disorders involving anxiety or phobia and is designed to have rapid onset. Self-administered in microgram-level doses, in Phase 2 studies for the treatment of social anxiety disorder (SAD), PH94B produced rapid-onset (within approximately 15 minutes) anti-anxiety effects without sedation or systemic uptake and distribution.

VistaGen is currently preparing PH94B for Phase 3 development as a potential acute treatment of anxiety in adults with SAD. The FDA has granted Fast Track designation for the development of PH94B for this indication.

With rapid-onset pharmacology and favorable safety results seen in all clinical studies to date, we believe PH94B has the potential to provide an innovative treatment alternative to benzodiazepines and other pharmacological alternatives in the acute drug treatment paradigm for SAD, as well as others anxiety disorders.

About PH10
PH10 is an innovative odorless investigational synthetic neuroactive nasal spray designed to have rapid onset and therapeutic potential in several neuropsychiatric indications involving depression and suicidal ideation. Following successfully completed exploratory Phase 2A clinical development, VistaGen is preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for major depressive disorder (MDD).

About VistaGen
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

Forward Looking Statements
Various statements in this release are “forward-looking statements” concerning VistaGen’s future expectations, plans and prospects, including the potential for successful clinical development and commercialization of PH94B for anxiety disorders and PH10 for depression disorders. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: development and approval of PH94B and PH10 may not be achieved in any market; the FDA may decide that the results of the Company’s PH94B and PH10 clinical programs are not sufficient for regulatory approval for acute treatment of anxiety in adult patients with SAD or MDD, respectively, or any other anxiety- or depression-related disorder; development of PH94B and PH10 may not be successful in any indication; success in nonclinical studies or in earlier-stage clinical trials may not be repeated or observed in future studies, which may not support further development or be sufficient to gain regulatory approval to market PH94B or PH10; adverse events may be encountered at any stage of development that negatively impact further development. Other risks and uncertainties include, but are not limited to, issues related to: adverse healthcare reforms and changes of laws and regulations; general industry and market conditions; manufacturing and marketing risks, including risks related to the COVID-19 pandemic, which may include, but are not limited to, unavailability of or delays in delivery of raw materials for manufacture of PH94B or PH10; inadequate and/or untimely supply of PH94B or PH10 to meet demand; entry of competitive products; and other technical and unexpected hurdles in the development, manufacture and commercialization of PH94B and PH10, as well as those risks more fully discussed in the section entitled “Risk Factors” in VistaGen’s Annual Report on Form 10-K for the year ended March 31, 2020, and in its most recent Quarterly Report on Form 10-Q for the quarter and six months ended September 30, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/vistagen-therapeutics-expands-rd-team-with-appointment-of-louis-monti-md-phd-pioneer-in-the-development-of-neuroactive-steroids-known-as-pherines-as-potential-treatments-for-anxiety-and-depression-disorders-as-vice-presid-301182559.html

SOURCE VistaGen Therapeutics

NEW YORK, Dec. 1, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

• TTNP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=TTNP&prnumber=120120201
• MRNA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MRNA&prnumber=120120201
• MBRX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MBRX&prnumber=120120201
• CRBP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CRBP&prnumber=120120201
• ALT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ALT&prnumber=120120201

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-titan-pharmaceuticals-moderna-moleculin-biotech-corbus-pharmaceuticals-or-altimmune-301182574.html

SOURCE InvestorsObserver

ROCHESTER, N.Y., Dec. 1, 2020 /PRNewswire/ — The latest Paychex |IHS Markit Small Business Employment Watch shows that small business hiring remained largely consistent with the prior month, moderating slightly, down 0.03 percent nationally to 94.29. In November, hourly earnings growth stood at 2.76 percent, while weekly hours worked showed a decrease of 0.04 percent year over year.

“The Index has been essentially flat since August, showing no signs of immediate recovery,” said James Diffley, chief regional economist at IHS Markit.

“As the pandemic reaches yet another peak in the U.S., both employment and wage growth have remained relatively steady over the past quarter,” said Martin Mucci, Paychex president and CEO. “Despite the recent surge, small businesses across the U.S. continue to show resiliency, validating other key metrics we monitor that have been showing similar trends.”

The report also includes regional, state, metro, and industry level analysis, showing:

• The South remains the top-ranked region for employment growth, a full one point above the next highest region.
• The Northeast is the only region with weekly earnings growth above three percent.
• Texas has climbed one spot in the rankings each month for the past quarter, now ranking first among states in job growth.
• Construction leads all industries in job growth for the seventh consecutive month.
• Leisure and Hospitality lags with the weakest index for the past eight months.

The complete results for November, including interactive charts detailing all data at a national, regional, state, metro, and industry level, are available at www.paychex.com/employment-watch. Highlights are available below. 

Note: Data presented for the month of November was collected from Friday, October 16 through Thursday, November 19, the cutoff date for the Small Business Employment Watch.

National Jobs Index

• Since dropping below 95 in April, the national index has moderated between 94 and 95 for the past seven months.
• At 94.29, the Small Business Jobs Index slowed 0.03 percent in November and 3.89 percent from last year.
• The national index reached a new low for the second consecutive month.

National Wage Report

• Hourly earnings growth slowed for the fifth consecutive month, from a peak of 3.29 percent in June to 2.76 percent in November.
• At -0.04 percent in November, weekly hours worked growth turned negative for the first time since May; one-month and three-month annualized growth were both down more than one percent for the second consecutive month.
• Weekly earnings reported growth below three percent for the first time since September 2019.

Regional Jobs Index

• There was very little movement across the four major regions in November, as each edged down very slightly.
• At 95.62, the South remains the top-ranked region and is one point above the next highest region, the Midwest (94.62).
• The West remains the lowest-ranked region for the third consecutive month, reaching a new historic low for the fourth consecutive month.

Regional Wage Report 

• The Northeast is the only region with weekly earnings growth above three percent, though it has quickly slowed from a June peak of 7.35 percent.
• Earnings and hours worked growth is weakest in the South.
• Hourly earnings growth has slowed for 12 consecutive months in the West, from 3.41 percent last November to 2.63 percent this November.

State Jobs Index

• Texas gained 0.63 percent in November, moving ahead of Florida for the top-ranked state index at 96.73; Texas has climbed one spot in the rankings each month for the past quarter, gaining 1.01 percent.
• Though Washington is the weakest state index for the fifth straight month, it has improved 0.71 percent during the past quarter.
• Virginia fell 1.69 percent and in November, pulling its index down nine spots among states to 93.70.

Note: Analysis is provided for the 20 largest states based on U.S. population.

State Wage Report

• New Jersey, Massachusetts, and Pennsylvania lead hourly earnings growth among states, all above four percent, though one-month and three-month annualized growth rates are signaling a slowdown.
• Florida and Georgia have the weakest weekly hours worked growth among states, both down more than one percent year-over-year.
• With hourly earnings growth up one percent and weekly hours worked growth down one percent, weekly earnings growth in Texas is just 0.01 percent, last among states.

Note: Analysis is provided for the 20 largest states based on U.S. population.

Metropolitan Jobs Index 

• The gap in metro performance shrunk in November as top-ranked Denver declined 0.80 percent and lowest-ranked Seattle increased 1.05 percent.
• Dallas spiked 1.05 percent to 97.22, while Houston moderated -0.08 percent with an index level of 95.39.
• Baltimore recovered 1.15 percent this past month as its index is now down just 1.28 percent from last year.

Note: Analysis is provided for the 20 largest metro areas based on U.S. population.

Metropolitan Wage Report

• With hourly earnings growth of 5.88 percent, Riverside tops the metro rankings for the sixth straight month; Riverside weekly hours worked growth ranks second as well.
• Three metros have hourly earnings growth above four percent, while three metros have hourly earnings growth below two percent.
• Tampa remains in the middle of the pack for earnings and hours worked growth among metros, though one-month annualized growth for both dropped considerably in November, signaling weakening conditions.

Note: Analysis is provided for the 20 largest metro areas based on U.S. population.

Industry Jobs Index

• There was little change among industries in November; Construction leads all industries for the seventh consecutive month, while Leisure and Hospitality lags with the weakest index for the past eight months.
• Six of the eight industry sectors are above the national index level (94.29) as Manufacturing (92.73) and Leisure and Hospitality (88.14) are pulling down the national level of small business employment growth.

Note: Analysis is provided for seven major industry sectors. Definitions of each industry sector can be found here. The Other Services (excluding Public Administration) industry category includes religious, civic, and social organizations, as well as personal services, including automotive and household repair, salons, drycleaners, and other businesses.

Industry Wage Report 

• Leisure and Hospitality ranks first among sectors in hourly earnings growth (4.15 percent) and last in weekly hours worked growth (-2.44 percent).
• At 3.76 percent, Construction leads in weekly earnings growth among sectors and is the only sector with one-month and three-month growth above three percent.
• Unlike other sectors, Financial Activities did not experience a significant disruption in weekly hours worked as growth has been steadily positive and consistent during 2020.

Note: Analysis is provided for seven major industry sectors. Definitions of each industry sector can be found here. The Other Services (excluding Public Administration) industry category includes religious, civic, and social organizations, as well as personal services, including automotive and household repair, salons, drycleaners, and other businesses.

For more information about the Paychex | IHS Markit Small Business Employment Watch, visit www.paychex.com/employment-watch and sign up to receive monthly Employment Watch alerts.

*Information regarding the professions included in the industry data can be found at the Bureau of Labor Statistics website.

About the Paychex | IHS Markit Small Business Employment Watch

The Paychex | IHS Markit Small Business Employment Watch is released each month by Paychex, Inc., a leading provider of payroll, human resource, insurance, and benefits outsourcing solutions for small-to medium-sized businesses, and IHS Markit, a world leader in critical information, analytics, and expertise. Focused exclusively on small business, the monthly report offers analysis of national employment and wage trends, as well as examines regional, state, metro, and industry sector activity. Drawing from the payroll data of approximately 350,000 Paychex clients, this powerful tool delivers real-time insights into the small business trends driving the U.S. economy.

About Paychex
Paychex, Inc. (NASDAQ:PAYX) is a leading provider of integrated human capital management solutions for payroll, benefits, human resources, and insurance services. By combining its innovative software-as-a-service technology and mobility platform with dedicated, personal service, Paychex empowers small- and medium-sized business owners to focus on the growth and management of their business. Backed by more than 45 years of industry expertise, Paychex served more than 680,000 payroll clients as of May 31, 2020 across more than 100 locations in the U.S. and Europe, and pays one out of every 12 American private sector employees. Learn more about Paychex by visiting paychex.com and stay connected on Twitter and LinkedIn.

About IHS Markit (www.ihsmarkit.com)
IHS Markit (NYSE: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.

IHS Markit is a registered trademark of IHS Markit Ltd. and/or its affiliates. All other company and product names may be trademarks of their respective owners © 2020 IHS Markit Ltd. All rights reserved.

Media Contacts

Lisa Fleming

Paychex, Inc.
+1 585-387-6402
[email protected] 
@PaychexNews 

Kate Smith

IHS Markit
+1 781-301-9311
[email protected] 

Colleen Bennis

Mower
+1 585-389-1865
[email protected] 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/key-indicators-of-small-business-employment-show-stability-amid-recent-surge-in-covid-19-cases-across-the-us-301182577.html

SOURCE Paychex, Inc.

Key changes to the Exchange’s most popular go-public vehicle aimed at deal makers

TORONTO, Dec. 1, 2020 /CNW/ – TSX Venture Exchange (TSXV) today announced changes to its Capital Pool Company (CPC) program, following extensive consultation with stakeholders across the TSXV community. The CPC program is a unique listing vehicle exclusively offered by TSXV and accounted for almost 50% of new TSXV listings in the past 10 years.

New changes to the policy will take effect on January 1, 2021 and will provide:

• Increased flexibility – new jurisdictions added, residency restrictions eased, spending restrictions simplified
• Reduced regulatory burden – relaxed requirements on shareholder distribution and shareholder approval, fewer restrictions on PRO subscriptions
• Improved economics – increased seed investment, finders fees, shorter escrow

“The CPC program is a unique, innovative go-public vehicle tailored to serve the needs of growth companies in all sectors and is the leading source of new listings on TSX Venture Exchange. We are proud of the program’s long track record of success in expanding opportunities for companies to access public growth capital,” said Loui Anastasopoulos, President, Capital Formation, TMX Group. “As the Canadian financial landscape continues to evolve, we recognize the importance of working together with our clients and stakeholders to ensure the services and solutions we provide to enable success remain relevant. We thank our partners across the community for working with us to identify significant ways we can enhance the CPC program and make these important policy changes.”

Representatives from both the provincial and national advisory committees will join TMX executives to open the market this morning at 9:30 a.m. EST.

The CPC program provides an alternative, two-step introduction to the capital markets by introducing investors with financial market experience to entrepreneurs whose growth and development-stage companies require capital and public company management expertise.

Since its inception in 1986, there have been over 2,600 CPCs created and more than 2,200 qualifying transactions (QTs) completed. Former CPCs have raised over $75 billion in equity capital on TSX and TSXV. TSXV will be hosting virtual events on December 8 and 9, 2020 to review the key policy changes. For more information, please visit tsx.com/cpc.

For Market Openings:

 Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact [email protected]. The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET.

About TMX Group (TSX:X) 

TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group’s key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, and Trayport which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London and Singapore. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter: @TMXGroup.

SOURCE TMX Group Limited

TORONTO, Dec. 1, 2020 /PRNewswire/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its first delivery of two (2) of a total of five (5) SKU’s ordered by MediPharm Labs Corp.  (TSE:LABS.TO) (OTC:MEDIF).  Further to Canntab’s press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million.  Canntab intends to complete and deliver the entire order by the end of 2020.

“Our first commercial production and delivery of this initial portion of our order from MediPharm Labs Corp. is a major milestone event for our company for three important reasons. First, this is evidence our science, quality assurance programs and production can be executed with the required standards to reflect our unique patented product of pressed tablets and caplets. Second, Canntab’s wide range of products will finally be available to all Canadians through a variety of retail and wholesale channels.  Finally, Canntab will be able to recognize revenue from its core product that will have a strong distribution base which will result in continuous sales through further expansion. Canntab will continue to enhance shareholder value by growing revenue through its domestic channels and expanding sales to international customers.” explains Larry Latowsky, Chief Executive Officer of Canntab.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Cautionary Statements 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward- looking statements are based on certain assumptions, including Canntab’s ability to fulfil the entire purchase order by the end of 2020, that the Company will continue to grow revenues through domestic channels and international expansion, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business. While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with delays in fulfilling MediPharm Labs Corp.’s purchase order, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada and internationally in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/canntab-begins-delivery-of-tablets-to-medipharm-301182565.html

SOURCE Canntab Therapeutics Limited

The new visionary CEO to execute her psychedelics strategy for transformational mental health care

VANCOUVER, BC, Dec. 1, 2020 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased today to announce the appointment of Kelsey Ramsden as President and Chief Executive Officer, effective immediately. With Over 15 years founding, scaling and operating innovative businesses across several industries, Mrs. Ramsden has built multiple eight-figure companies from the ground up. She is an experienced leader and acclaimed entrepreneur, twice recognized as Canada’s Top Female Entrepreneur of the Year. After serving as Mind Cure’s COO, Mrs. Ramsden steps into the President and CEO role as of December 1, 2020. She possesses a thorough understanding of the mental health industry and a clear vision of where it is going.

Mrs. Ramsden stated, “I am humbled and excited to step into the position of President and CEO at Mind Cure. I have a profound passion for this industry and finding a better way to treat mental health. Through firsthand experience I know the incredibly promising potential of new drugs, treatments and therapies and am excited to work with our team to bring them to people in need.”

After guiding Mind Cure through its initial public offering and early operations, former President and CEO Philip Tapley will continue to serve the Board of Directors as Chairman. It was obvious to him early on that Mrs. Ramsden was the right leader to continue to build upon what he started. “Mrs. Ramsden will take our strategic vision to new heights,” said Mr. Tapley. “We have earned the trust of the industry and our shareholders these past few months, and now we get to work to translate that into earning the trust of our customers and those in need of new mental health treatments. Mrs. Ramsden has the full support of our Board of Directors and the right strategic plan in place for Mind Cure to become an industry leader.”

Mind Cure aims to identify and develop the pathways transforming mental health and wellness. Its unique focus will provide doctors, clinicians, and health regulators with data-driven research to prove the efficacy of treatment for people suffering from mental health illnesses and looking for a new way forward. “There are many promising companies, areas of research and studies emerging every single day in our industry. I will ensure that everything we do at Mind Cure is built on trust and backed by science,” said Mrs. Ramsden. “This growing industry of psychedelics and new mental health treatments requires a paradigm shift away from the old way of doing things. I have done things differently as a leader throughout my career. This industry needs more individualization. Richer scientific rigor. More empathy and trust that is earned. This is how I plan to lead Mind Cure.”

About Mrs. Ramsden

Kelsey Ramsden has spent her life building and scaling businesses in unconventional ways. She was named one of Canada’s 100 most powerful women, won Canada’s #1 female entrepreneur two years in a row, and proudly serves as a Richard Branson Centre Mentor.

Mrs. Ramsden also serves on the Entrepreneurship Council for the University of Western Ontario. An accomplished keynote speaker and bestselling author, she holds an MBA from the Richard Ivey School of Business at the University of Western Ontario.

The Company has granted a total of 500,000 stock options to Mrs. Ramsden pursuant to the terms of her executive employment agreement and the Company’s incentive stock option plan (the “Plan”).  The stock options are exercisable at a price of $0.63 and subject to the terms of the Plan.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care. 

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Philip Tapley, Chairman
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mrs. Ramsden being named President and CEO of Mind Cure; Mrs. Ramsden having a clear vision of where Mind Cure needs to go; Mrs. Ramsden taking Mind Cure to new heights; Mind Cure becoming an industry leader; Mind Cure identifying and developing the pathways transforming mental health and wellness; Mrs. Ramsden’s plans to lead Mind Cure; Mind Cure earning the trust of the industry and its shareholders; Mrs. Ramsden having the right strategic plan in place.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian and global economy and Mind Cure’s business, and the extent and duration of such impact; Mrs. Ramsden’s plans to lead Mind Cure; Mrs. Ramsden building Mind Cure into an industry leader. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian and global economy, Mind Cure’s industry and its business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect its investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; the promotion of Mrs. Ramsden may not help Mind Cure achieve its goals.

Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mind-cure-promotes-kelsey-ramsden-to-president-and-chief-executive-officer-301182562.html

SOURCE Mind Cure Health Inc.

DENVER, Dec. 1, 2020 /PRNewswire/ — RE/MAX, LLC is partnering with kids to raise funds for Children’s Miracle Network (CMN) Hospitals. Starting today, Miracle Masks, a pack of three face coverings featuring artwork by a patient and siblings served by the organization, are available for purchase at rem.ax/MiracleMasks. The final designs were selected after receiving more than 15,000 votes on the RE/MAX Facebook and Instagram accounts. Each pack costs $30, with $15 from each sale donated to the buyer’s local CMN Hospital. 

The masks feature artwork by Ashton Zuri, age 10, who receives treatment for Chronic Kidney Disease at Nationwide Children’s Hospital in Columbus, Ohio; his sister Addison, age 7; and Sophia Erickson whose brother, Matthew, was treated for brain cancer at Ann & Robert H. Lurie Children’s Hospital of Chicago. RE/MAX worked with Approved Supplier and promotional supply company BlinkSwag to create the custom masks. The masks are available to purchase on the BlinkSwag website.

When brainstorming their designs, both Zari siblings said they wanted to impart positivity. Addison’s mask design encourages the wearer to “Dream Big,” while Ashton’s message to “Be A Kind-A-Saurus” instantly won the hearts of voters. 

“I made my mask to inspire people to be more kind, and I added a dinosaur because they’re one of my favorite things,” Ashton said. 

Sophia received the most votes out of the 30 designs featured in the social media campaign.

“I drew the CMN Hospitals logo and the word hope because CMN Hospitals gives so much hope to our family and many other families,” Sophia said. “When my mom tells my brother’s story, she mentions hope a lot. And now with coronavirus going on, everybody needs a little bit of hope right about now.”

The Covid-19 pandemic has severely impacted fundraising for the 170 member CMN Hospitals. In a Q2 survey, hospitals reported losing an average of $67 million in revenue. At the same time, 67% of hospitals indicated they would not be able to meet their needs in the next year without increases in donations. 

“During the Covid-19 pandemic, hospital donations have decreased at a time when costs are increasing and the need for care is greater than ever,” said Kayla Roofe, Senior Social Media Manager for RE/MAX who helped organize the campaign. “Our hope is that funds raised through the Miracle Mask campaign will help fill this critical gap. Giving Tuesday is a great reminder that we’re all in this together, and it’s important to support organizations doing good in your community. Helping kids and their families is a wonderful cause to support on this national day of giving.”

The Miracle Mask campaign is just the beginning of a season of RE/MAX fundraising for CMN Hospitals. A virtual auction with luxury items, including a Ferragamo Italian leather handbag, a case of rare wine, and a private villa in Cabo San Lucas, also launched today at www.bidpal.net/miracleauction. Additionally, RE/MAX affiliates are organizing virtual toy drives around the country to help fight isolation and bring joy to patients of their local children’s hospital this holiday season.

“Now, more than ever, RE/MAX agents are united in their mission to help kids get the care they need,” says Mike Reagan, RE/MAX Senior Vice President of Industry Relations and Global Growth & Development. “CMN Hospitals offer leading treatment, support, and most of all, hope, for patients and their families, and we’re proud to partner with them in their mission.”

RE/MAX became a corporate sponsor of CMN Hospitals in 1992. The RE/MAX Miracle Home Program, where many agents make a donation after a closed transaction, is the cornerstone of the partnership. Agents also raise funds in a variety of other ways, including organizing live auctions and hosting community festivals. In April, it was announced that the grand total of donations since the partnership began had crossed the $160 million mark.

About the RE/MAX Network
As one of the leading global real estate franchisors, RE/MAX, LLC is a subsidiary of RE/MAX Holdings (NYSE: RMAX) with over 135,000 agents in more than 110 countries and territories. Nobody in the world sells more real estate than RE/MAX, as measured by residential transaction sides. Dedicated to innovation and change in the real estate industry, RE/MAX launched Motto Mortgage, a ground-breaking mortgage franchisor, in 2016 and acquired booj, a real estate technology company, in 2018. RE/MAX agents have lived, worked and served in their local communities for decades, raising millions of dollars every year for Children’s Miracle Network Hospitals® and other charities. To learn more about RE/MAX, to search home listings or find an agent in your community, please visit www.remax.com. For the latest news about RE/MAX, please visit news.remax.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/remax-launches-miracle-mask-campaign-to-benefit-childrens-miracle-network-hospitals-301182483.html

SOURCE RE/MAX, LLC